The UK has been on a losing streak for too long. But the clouds seem to be lifting and Britons are beginning to win again.

Novartis hopes of bringing Cosentyx to patients with giant cell arteritis seem to be over after the drug missed all the endpoints in a phase 3 trial.

A polygenic risk score (PRS) test analyses hundreds to millions of DNA variants to generate a personal risk score for ...